David Bearss, Halia Therapeutics CEO
December 10, 2024 10:34 AM EST
R&D

Halia Ther­a­peu­tics takes NL­RP3 in­hibitor in­to fi­nal stage of Phase 2 tri­al

Katherine Lewin

News Reporter

Halia Ther­a­peu­tics is mov­ing its lead as­set in­to the sec­ond part of a mid-stage tri­al fol­low­ing ini­tial pos­i­tive da­ta in pa­tients with an ear­ly form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Can the Pfiz­er ma­chine fight back against an ac­tivist in­vestor?

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

Lykos up­heaval con­tin­ues with four new board ex­its amid hunt for cash

Umo­ja’s $100M Se­ries C will ad­vance its bid for more con­ve­nient cell ther­a­pies

FTC goes af­ter phar­ma mid­dle­men's price hikes on 'spe­cial­ty' drugs

A service from the Financial Times